EMBRACE - Early detection of Brain Cancer using a novel spectroscopic liquid biopsy enabling timely detection and diagnosis for patient benefit

A simple blood test could replace brain scans as the first step in diagnosing brain cancer. Dxcover, a diagnostics company, has developed a technology that uses infrared light to detect signals from a tumour and the body’s response to it, all from a small blood sample. This matters because brain cancer is typically caught late, when treatment options are limited. The current diagnostic pathway is inefficient: most people referred for imaging do not have cancer, wasting time and resources. If this test gains regulatory approval, it could slot into routine clinical care as a fast, affordable triage tool. Patients with suspicious symptoms would receive a blood test first, and only those with positive results would proceed to imaging. That would streamline the diagnostic pathway, reduce unnecessary scans, and speed up treatment for those who need it. The project focuses on obtaining regulatory approval and entering the European market, moving a validated technology from clinical studies into everyday medical practice.